| Cannabidiol: State of the art and new challenges for therapeutic applications S Pisanti, AM Malfitano, E Ciaglia, A Lamberti, R Ranieri, G Cuomo, ... Pharmacology & therapeutics 175, 133-150, 2017 | 631 | 2017 |
| N6-isopentenyladenosine dual targeting of AMPK and Rab7 prenylation inhibits melanoma growth through the impairment of autophagic flux R Ranieri, E Ciaglia, G Amodio, P Picardi, MC Proto, P Gazzerro, ... Cell Death & Differentiation 25 (2), 353-367, 2018 | 61 | 2018 |
| Deregulated expression and activity of Farnesyl Diphosphate Synthase (FDPS) in Glioblastoma M Abate, C Laezza, S Pisanti, G Torelli, V Seneca, G Catapano, ... Scientific reports 7 (1), 14123, 2017 | 43 | 2017 |
| Current status and future perspectives in targeted therapy of NPM1-mutated AML R Ranieri, G Pianigiani, S Sciabolacci, VM Perriello, A Marra, V Cardinali, ... Leukemia 36 (10), 2351-2367, 2022 | 40 | 2022 |
| Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML I Gionfriddo, L Brunetti, F Mezzasoma, F Milano, V Cardinali, R Ranieri, ... Leukemia 35 (9), 2552-2562, 2021 | 28 | 2021 |
| Endocannabinoid system in neurological disorders R Ranieri, C Laezza, M Bifulco, D Marasco, A M Malfitano Recent Patents on CNS Drug Discovery (Discontinued) 10 (2), 90-112, 2015 | 28 | 2015 |
| Recognition by natural killer cells of N6‐isopentenyladenosine‐treated human glioma cell lines E Ciaglia, C Laezza, M Abate, S Pisanti, R Ranieri, A D'alessandro, ... International Journal of Cancer 142 (1), 176-190, 2018 | 24 | 2018 |
| Impact of drought on human health M Bifulco, R Ranieri European Journal of Internal Medicine 46, e9-e10, 2017 | 16 | 2017 |
| The isoprenoid derivative N6‐benzyladenosine CM223 exerts antitumor effects in glioma patient‐derived primary cells through the mevalonate pathway E Ciaglia, M Grimaldi, M Abate, M Scrima, M Rodriquez, C Laezza, ... British journal of pharmacology 174 (14), 2287-2301, 2017 | 15 | 2017 |
| Phytocannabinoids and cannabimimetic drugs: recent patents in central nervous system disorders R Ranieri, D Marasco, M Bifulco, A M Malfitano Recent Patents on CNS Drug Discovery (Discontinued) 10 (2), 157-177, 2015 | 15 | 2015 |
| Cannabinoids and neuro-inflammation: regulation of brain immune response R Ranieri, C Laezza, M Bifulco, D Marasco, A M Malfitano Recent Patents on CNS Drug Discovery (Discontinued) 10 (2), 178-203, 2015 | 11 | 2015 |
| SiCoDEA: a simple, fast and complete app for analyzing the effect of individual drugs and their combinations G Spinozzi, V Tini, A Ferrari, I Gionfriddo, R Ranieri, F Milano, ... Biomolecules 12 (7), 904, 2022 | 10 | 2022 |
| Non-invasive respiratory support in SARS-CoV-2 related acute respiratory distress syndrome: when is it most appropriate to start treatment? R Nevola, A Russo, S Scuotto, S Imbriani, C Aprea, M Abitabile, D Beccia, ... Respiratory Research 23 (1), 327, 2022 | 9 | 2022 |
| Platypnea-orthodeoxia syndrome in SARS-CoV-2 related ARDS: a case report C Aprea, S Imbriani, G Cirigliano, K Gjeloshi, LA Meo, A Padula, ... Acta Bio Medica: Atenei Parmensis 93 (Suppl 1), 2022 | 5 | 2022 |
| Impact of thyroid cancer treatment on renal function: A relevant issue to be addressed R Di Paola, A De, A Capasso, S Giuliana, R Ranieri, C Ruosi, A Sciarra, ... Journal of Personalized Medicine 13 (5), 813, 2023 | 4 | 2023 |
| Comparison of the risk of cardiovascular diseases, stroke, and diabetes among the selected group of football referees and the group of general population men from Northern … J Wesołowska, A Jurczak, S Wieder-Huszla, K Jarosz, A Jurewicz, ... European Review for Medical & Pharmacological Sciences 26 (9), 2022 | 1 | 2022 |
| Brain cancer risk: the weight of obesity M Bifulco, R Ranieri, E Ciaglia Journal of neuro-oncology 131, 421-422, 2017 | 1 | 2017 |
| Poster: AML-377 A “Designed” High-Throughput Drug Screening Strategy Identifies Aurora Kinase A Inhibitors as Promising Preclinical Candidates for the Treatment of NPM1-Mutated AML R Ranieri, M Neuenschwander, S Kleissle, F Mezzasoma, S Silvestri, ... Clinical Lymphoma, Myeloma and Leukemia 22, S134, 2022 | | 2022 |
| AML-377 A “Designed” High-Throughput Drug Screening Strategy Identifies Aurora Kinase A Inhibitors as Promising Preclinical Candidates for the Treatment of NPM1-Mutated AML R Ranieri, M Neuenschwander, S Kleissle, F Mezzasoma, S Silvestri, ... Clinical Lymphoma Myeloma and Leukemia 22, S242, 2022 | | 2022 |
| ISOCITRATE DEHYDROGENASES AML-ASSOCIATED POINT MUTATIONS DRIVE A BLOCK OF DIFFERENTIATION IN HUMAN NORMAL CD34+ HEMATOPOIETIC CELLS THAT IS RELEASED BY SPECIFIC INHIBITORS S Pierangeli, V Ciaurro, S Donnini, F Milano, M Sabino, I Gionfriddo, ... HAEMATOLOGICA 107, 50-50, 2022 | | 2022 |
